Use of the temporary glycemic target feature in the medtronic MiniMed™ 780G advanced hybrid closed loop system: a real-world evidence study

Aim: The MiniMed™ 780G system utilizes an Advanced Hybrid Closed-Loop algorithm, which is optimized to perform best at a glucose target of 100 mg/dL. The system also includes a temporary target feature (TT) of 150 mg/dL that can be set when higher glucose utilization is anticipated (e.g., exercise/strenuous work). Methods: Real-world data from 1002 randomly selected users of the MiniMed™ 780G and MiniMed™ 670G systems were used to investigate the TT functionality (n = 501 MiniMed™ 780G users, n = 501 MiniMed™ 670G users). Continuous glucose monitoring (CGM) metrics were calculated for 4-h intervals (4 h prior to commencing TT use and 0–4, 4–8, 8–12, 12–16, 16–20 and 20–24 h after TT initiation). Results: CGM results showed that, with both systems, the time-in-range (TIR) during TT periods mostly equalled or exceeded TIR in corresponding non-TT periods. In the first 4 h after TT initiation, the MiniMed™ 780G system demonstrated a TIR and time in tight range (TITR) of 71.6% and 46.4%, respectively, [a 1.6 (p = 0.11) and 2.6 (p = 0.009) percentage point benefit in TIR and TITR, respectively, versus the 670G system]. Mean time-below-range remained below target in both periods. Conclusions: These findings confirm that the TT setting performs as intended, allowing users to maintain TIR during strenuous activity without compromising safety.